Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » DNAG possible big move (Page 1)

 - UBBFriend: Email this page to someone!   This topic comprises 4 pages: 1  2  3  4   
Author Topic: DNAG possible big move
beto
Member


Rate Member
Icon 1 posted      Profile for beto     Send New Private Message       Edit/Delete Post   Reply With Quote 
This is looking very good on the graph. We're up to .028 right now. Looks like something is up.
Posts: 36 | From: North East | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
AtHomeDad
Member


Rate Member
Icon 1 posted      Profile for AtHomeDad     Send New Private Message       Edit/Delete Post   Reply With Quote 
Beto, This is a slow mover. It just needs time, but I'll take sooner rather then later.

I normally HATE the word Diversity, but this Co. has good diversification. My bet is on the Pharm that will make this thing jump.

ABOUT US

DNAPrint™ genomics, Inc. is a cutting edge company. We are concentrating our efforts in four distinct areas; Pharmacogenomics, Forensics, Genotyping, and Consumer Products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.

The Company’s core patent applied for and proprietary technologies for efficiently targeting single nucleotide polymorphisms (“SNPs”) enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors.

We have identified and applied for patenteds to cover the maps of certain SNPs that we believe have broad commercial applications. These commercially valuable SNPs are called Ancestry Informative Markers (“AIMs”) and are an integral part of our proprietary Admixture Mapping (“Mapping”) method. With our mapping, we leverage known statistical data about population structure to substantially reduce the number of SNPs analyzed and therefore more cost effectively identify genes responsible for certain traits. Our proprietary data and analytical resources for using AIMs are integral to our strategy of offering DNA tests that provide value in other ways too – from better study design using more traditional methods, and generating valuable predictive results, including a person’s physical characteristics, BioGeographical Ancestry (“BGA”), and predisposition to respond to certain pharmaceutical drugs.

WE ARE CURRENTLY FOCUSING OUR EFFORTS IN FOUR DISTINCT MARKETS:

Consumer DNA Products Market - There is an established market of consumers who recreationally research their genealogy and ancestral origin but only recently has it become possible to apply modern advances in genome technology to this endeavor. AncestryByDNA, the flagship product of our Genealogy line of services and products, now makes it affordable for the general public to use the power of genomics to discover their genetic ancestry. This is a great tool for individuals or groups interested in more deeply and scientifically exploring their genetic heritage and often customers are able to learn something about their lineage that is several thousand years old. By submitting a DNA sample to our lab, customers receive an impressive and detailed analysis of their BioGeographical origins

Forensics DNA Testing Market - Testing DNA to create a physical description from crime scene DNA and provide a photo database array of representative closely matching the analyzed DNA allows detectives a means of describing ‘persons of interest’. This presumptive test method is a new market based on evolving DNAPrint genomics technologies. Common hereditary traits such as skin pigmentation, eye color, hair color, facial geometry and even height can be predicted through analysis of DNA sequences. This can be done indirectly, through an extensive knowledge of ancestry admixture or for certain genetic traits, directly through knowledge of the underlying genes. At DNAPrint™ we use both methods. Our goal is to continue to lead the field of forensic presumptive testing using our DNAWitness line of products and services.

Pharmacogenomics Market - The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition. We at DNAPrint believe that as doctors and health care providers have been reporting for thousands of years; that different peoples from different countries have variable responses to medications is reason enough for us to explore this realm of medicine. We hope to be able to help predict whether a woman taking a chemotherapy agent for a cancer will respond favorably to a drug. We also will apply our technology to our own therapeutics, such as PT-401 a ‘super EPO’ and help improve the efficacy of the drug therapy going into clinical evaluation as well as helping to improve and maintain patient response efficacy after the drug is approved. Pharmaceutical and pharmaceutical diagnostics are important cornerstones for our future value to our shareholders. We believe individualized medicine, while still some years away, will be here to stay, especially now that the U.S. FDA has written about pharmacogenomics. view PDF

Contract Service Outsourcing Market - DNAPrint™ provides universities and drug discovery companies with genotyping services. The service provides our clients with the ability to screen efficiently and effectively for genes that may be responsible for certain human traits and/or disease states.

We see exciting growth opportunity in these markets to introduce and sell our novel products and services. Few Universities and Medical centers can afford to invest millions of dollars and spend years of research time developing a methodology that DNAPrint can make readily available to them at a competitive and economical rate. We continue to improve our laboratory’s throughput capacity and lowered our per genotype costs on our Ultra High Throughput SNP machine.

--------------------
Veni Vidi Vici

Posts: 529 | From: CA | Registered: Jan 2005  |  IP: Logged | Report this post to a Moderator
AtHomeDad
Member


Rate Member
Icon 1 posted      Profile for AtHomeDad     Send New Private Message       Edit/Delete Post   Reply With Quote 
more PR on R&D

Updated:2006-03-03 07:41:53
DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences
Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 03/03/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.

The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.

DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to ensure that patients receive the appropriate medicine and proper dosage based on a patient's genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.

"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."

According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."

"Many researchers believe that a strong link exists among drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."

--------------------
Veni Vidi Vici

Posts: 529 | From: CA | Registered: Jan 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Good post, im definitely hangin on this one, great potential

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
What keeps a stock like DNAG from breaking out to a higher pps on such large volume? Anyone that has ideas on this, I would love to hear them. Thanks

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Market Pulse Breaking News Alert for Tuesday, March 7, 2006: DNAG -- DNAPrint Genomics Scientist to Co-Chair Discussion on "Genetic Testing" at the American Association of Physical Anthropologists Annual Meeting!

By Market Wire
Last Update: 3/7/2006 8:50:02 AM
Data provided by

ATLANTA, GA,, Mar 07, 2006 (MARKET WIRE via COMTEX) -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (DNAG), Ivanhoe Energy Inc. (IVAN), Finisar Corp. (FNSR) and Quest Communications International Inc. (Q).

Investors need to be watching DNAPrint Genomics, Inc. (DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing that their scientist Dr. Ripan Malhi will co-chair a discussion on genetic testing at the American Association of Physical Anthropologists annual meeting! Investors should be watching this one closely!

DNAPrint Genomics, Inc. (DNAG) today announced that Dr. Ripan Malhi will co-chair a symposium of 14 scientists and business persons for a discussion of ethical and sociopolitical issues surrounding consumer genetic testing as part of the 75th annual meeting of the American Association of Physical Anthropologists in Anchorage, Alaska. Dr. Malhi is the Senior Research Director of Trace Genetics, Inc., the Company's wholly owned subsidiary. The four-day meeting, which begins Wednesday, March 8, features several symposiums and poster discussions. This symposium focuses on the interpretation of genetic test results and the public's understanding of race, ethnicity, human genetic variation and evolutionary history of the human species.

"The purpose of this symposium is to have a rigorous discussion of lineage based and whole genome tests exploring the anthropological, biomedical, and societal applications of genetic ancestry testing," explains Dr. Malhi. "It should be a lively discussion. We have purposefully brought together competent spokespersons with diverse perspectives. This will be an opportunity for opinions to be expressed and challenged and, ideally, allow the group as a whole to resolve issues in a direct and productive manner."

The symposium brings together scientists and experts from academia and private enterprise in an effort to build a consensus about how the public might best use genetic testing to understand their own ancestry within a valid scientific framework. Recent television specials and news publications have spurred public interest in genetic testing, resulting in the recent purchase by consumers of more than 150,000 genetic ancestry tests. The popularity of these genetic tests reflects a widespread interest by the public in using DNA technology to learn about family ancestry. Many anthropologists are concerned that the interpretation of the results of these tests may not give a complete and accurate picture of an individual's personal genetic history.

"Until recently the only way genealogists could determine their ancestors' origins was through records and oral history that traced ancestors as far back as the documentation existed. Now, genetic tests can reveal remote anthropological ancestry and suggest proportions of various ethnic and geographical origins such as Native American ancestry, in a given person's heritage. Genealogists should use the information for the test's intended purpose as one piece of a large and complex puzzle and avoid prejudice based on what they hoped they would find," commented Dr. Tony Frudakis, Chief Scientific Officer for DNAPrint Genomics.

The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine.

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Attention in particular to the last line of that article...


"The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine."

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
pps is controlled by the MMs. They
have their time table for each stock.
Good news will not work if they are
not ready to run it. CLBE, JKRI, and
GLIF got a run without any PR. XKEM
got a pull-down on news. AMEP and DNAG
are waiting for their turns. So just
be patient, when the MMs are ready,
it will run. Trust the MMs' ability
to pump.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
DNAG: the MMs have collected tons of
cheap shares, so must we.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Great great reply JimSC, thankyou

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
NEWS: http://biz.yahoo.com/iw/060309/0112547.html

Press Release Source: DNAPrint Genomics, Inc.

Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.
Thursday March 9, 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Mar 9, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively.


The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage.

"Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection."

"Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded.

Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at:

http://www.dnaprint.com/welcome/press/press_recent/2006/0126/ DNAG-HARVARD.pdf

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

Company Contact:
Richard Gabriel
CEO and President
(941) 366-3400

Ron Stabiner
The Wall Street Group, Inc.
(212) 888-4848


Source: DNAPrint Genomics, Inc.

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
Up 2.5% with huge volume. L2 lineup
is ready for a run.
Watch it.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
JimSC-
She's right at the pivot point of .0241 here
I see some resistence at around .025 and more at .03.
RSI looks good at 55
float 130m
O/S 150m
Level 2 looks good.
How high do you think she'll blow?
Do you see this as a quick popper or slow and steady?

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
0.0242 X 0.0245

up 4.2%.

The MMs are ready to let her go.

Watch it.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
If it breaks .025 (Nite) it should cruise into .03 and that looks like the showdown right now because there isn't alot of resistance between .03 and .10. Would like to see a nice steady three day run on this one.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
She's through .025! Must have been a fake wall. Let's see if we can run it up to .03 now. Looks like MM's are setting up camp at .03 to try to cap it.
5mms at .03 ask.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Wall at .026 held the first time. Let's see if we can get through it later today.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Forrestgump
Member


Rate Member
Icon 1 posted      Profile for Forrestgump         Edit/Delete Post   Reply With Quote 
I like the Chart...
Posts: 1335 | Registered: Oct 2003  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Alot of shares (500,000)traded between 11:30-12:00 at or above .026. Should make it a little easier to poke through if we get up that high again today.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ask * .026 V 10.5M

Market Pulse Breaking News Alert for Thursday, March 9, 2006: DNAG -- Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.


Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell. DNAPrint today announced that Harvard University has received formal Notice of Allowance from the U. S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company! Investors should be watching this one closely!

--------------------
w i k i s t o c k . c o m

Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Bid stacking up here 4 * .025
Nite(axe) at .026 on ask though

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Couldn't beat nite today. Nite finished at .0257 on ask. As usual I think if you watch Nite on level 2 you can figure out where the pps is going.
Good news is we saw alot of buys at the .0257 price which will hopefully soften that up for tomorrow.
Sorry if I'm annoying anyone by chattering so much. Pay no attention to me. Heck I probably don't know what I'm talking about anyway!

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
Looks like the MMs intend to make
DNAG run like IMNR, which jumped up
400% in 4 weeks after a few siwings.
So, just be patient and hold your
shares tight. IMO.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 7 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Keep talking John, I enjoy reading any insight or opinion you have. Who doesnt like to know what others are thinking?
Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
djequipment
Member


Rate Member
Icon 1 posted      Profile for djequipment     Send New Private Message       Edit/Delete Post   Reply With Quote 
I have commented in one of the other threads. I flipped DNAG for over 100% on it's last run from .02 to .04+.

I've been holding for a while * .023, and I feel the rumblings a coming for some more DNAG $$$.

Posts: 119 | From: Attleboro,MA USA | Registered: Nov 2004  |  IP: Logged | Report this post to a Moderator
JimSC
Member


Member Rated:
4
Icon 1 posted      Profile for JimSC     Send New Private Message       Edit/Delete Post   Reply With Quote 
Thanks to JohnWayne for sharing his DD with
us.

Posts: 3228 | From: Michigan | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Thanks guys for your kind words. But it's only fair I let you know I am a newby so please do not rely on my limited insight and experiences to make any decisions. Hah Hah. I always wanted to say that.
Good luck to all.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Level 2 looking sweet right now!I do have 15 minute delay on mine but let's hope it holds up.
bid - 5*.025
ask - 1*.0259
3*.026 (Nite)

500,000 buy pre-market!

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
.0259 ask can't hold much longer. Alot of buys going through at .0259
bid is 4*.0255

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Volume slowed and bid is weakening. Looks like we are slowing down for now!!!!

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Spread has widened to put the brakes on this.
Nobody selling at .0241 bid. A standoff!

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 6 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Lunch
Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Yeah lunch, as I bite into my 6 inch subway tuna sandwich, but now Nite is on the ask at .025.
He will bottle this up for most of the day. Hope for an EOD run, and then news on Monday.

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Johnwayne
Member


Rate Member
Icon 1 posted      Profile for Johnwayne     Send New Private Message       Edit/Delete Post   Reply With Quote 
Well earlier this morning I noticed the bid dropped to .023 while ask stayed at .0255.
Usually if the bid drops and ask doesn't than it's mm's trying to shake some shares free!

--------------------
Thanks Matto. Thanks Juice.

Posts: 2945 | From: USA | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
ehya
Member


Member Rated:
4
Icon 1 posted      Profile for ehya     Send New Private Message       Edit/Delete Post   Reply With Quote 
Thats interesting, never thought of that.
Posts: 234 | From: Gainesville, FL | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
  This topic comprises 4 pages: 1  2  3  4   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share